ReviewJournal of atherosclerosis and thrombosis2018
Pathophysiology of Diabetic Dyslipidemia.
Review in Journal of atherosclerosis and thrombosis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 267 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
267 citing papers in PubMed, 3 syntheses or guidelines pooled it, 514 citations in OpenAlex.
- The effects of Okra supplementation on blood pressure, lipid profile, and inflammation in patients with prediabetes, type 2 diabetes, and diabetic nephropathy: a meta-analysis and systematic review.Nutrition & diabetes · 2026Pooled it
- Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis StudiesEndocrine, metabolic & immune disorders drug targets · 2026Pooled it
- Efficacy and safety of variable-dose metformin as adjunctive therapy to insulin in adolescents with type 1 diabetes mellitus: a systematic review and network meta-analysis.BMC endocrine disorders · 2025Pooled it
- Effect ofNutrients · 2026Trial
- Glycemic and lipid responses to selenium-enriched vs. zeaxanthin-enriched eggs in patients with type 2 diabetes: a 12-week randomized controlled trial.Frontiers in nutrition · 2026Trial
- Review
- Integrated Cardio-Renal-Metabolic Risk Profiling in Patients with Type 2 Diabetes: A Machine Learning-Assisted Cross-Sectional Analysis.Journal of clinical medicine · 2026Article
- Aucubin Ameliorates Alloxan-Induced Diabetic Liver Injury in Association with Modulation of the Nrf2/HO-1 Antioxidant Axis and NF-κB-Associated Inflammatory and Apoptotic Signaling.International journal of molecular sciences · 2026Article
- Association Between the Triglyceride-to-HDL Cholesterol Ratio and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Real-World Retrospective Study.Biomedicines · 2026Article
- Article
- Lipoprotein X: artifactual lipid derangement in type 3c diabetes with obstructive liver disease.JCEM case reports · 2026Article
- Binaphthoquinone attenuates myofibroblast transition of human ventricular cardiac fibroblastsThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- Successful Management of Hypertriglyceridemia-Induced Acute Pancreatitis in Resource-Limited Setting: A Case Report and Brief Review of the Literature.Clinical case reports · 2026Article
- Biomarkers in Obesity-Related Metabolic Syndrome: Relationships Between LDL Subfractions, Lipid Profile, and Cardiometabolic Risk in a Slovak Population.Metabolites · 2026Article
- Assessment of Glycemic Control Among Prospective Hajj Pilgrims With Type 2 Diabetes Mellitus in Tangerang City, Indonesia.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Comparison of Bone Microarchitecture and Clinical Biomarkers between Diabetic and Non-Diabetic Postmenopausal Osteoporotic Women.Journal of bone metabolism · 2026Article
- Contrast enhanced ultrasound and laser doppler flowmetry capture distinct aspects of tissue microvascular perfusion in nonhuman primates.Physiological reports · 2026Article
- Multispectral Photoacoustic Imaging Detects Altered Hepatic Hemodynamics and Lipid in Early STZ-Induced Type 1 Diabetic Liver Injury.Journal of biophotonics · 2026Article
- Article
- Review
207 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.